HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


States With Age Restriction On OTC DXM Sales Number 17 – And Counting

This article was originally published in The Pink Sheet & The Rose Sheet

Executive Summary

Pennsylvania is 17th US state to limit sales of dextromethorphan OTCs to consumers 18 and older because teenagers' abuse of the ingredient for intoxicating effect remains a common problem.

You may also be interested in...

HBW Market Roundup: Prop 65 Amendment Off, Enforcement Discretion Asked For Label Compliance, More

California withdraws Prop 65 proposal to clarify when and how average concentrations can be calculated for a listed chemical due to deadline; trade groups ask FDA for enforcement discretion on compliance date for Nutrition and Supplement Facts labels rules; FDA published list of necessary records for FSVP applications; and use of OTC analgesics grows in teen suicide attempts.

Health Market News: DXM Sales Age-Restriction Bill Filed, E-Cigarettes Top NRTs In UK Trial

Resp. Matsui, Johnson again introduce bill for national age-18 requirement for OTC DXM sales; E-Cigarettes top NRTs for smoking cessation efficacy in UK trial.

Two States Require Industry To Pay For Ongoing Drug Take-Back Programs

Consumer Healthcare Products Association looks to stem expansion of state-mandated drug take-back programs with programs that use existing facilities and infrastucture and don't require industry funidng, says state affairs VP Carlos Gutierrez. State bills limiting sales of DXM to minors and expansion of the NPLEx system to track PSE sales also are on CHPA’s radar.

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts